Dose and Promoter Effects of Adeno-Associated Viral Vector for Green Fluorescent Protein Expression in the Rat Brain

Previous studies demonstrated that the rat neuron-specific enolase (NSE) promoter is effective for transgene expression in the brain in a variety of adeno-associated virus-2 vectors. This study evaluated the dose response and longer time course of this promoter and compared it to two cytomegalovirus/chicken beta-actin hybrid (CBA) promoter-based systems. NSE promoter-driven green fluorescent protein (GFP)-expressing neurons were found at doses as low as 10(7) particles, with expression increasing in a dose-dependent manner over a 3.3-log range. Bicistronic expression of GFP via an internal ribosome entry site coupled to the NSE promoter was also dose dependent, although the potency was decreased by 3.4-fold. The number of GFP-expressing neurons was stable for at least 25 months. The CBA promoter increased the numbers of GFP-expressing cells versus the NSE promoter, although the expression pattern remained neuronal and persisted for at least 18 months. The CBA promoter permitted detection of cells distal to the injection site that had retrogradely transported the vector from their terminal areas. Incorporating the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) into a CBA promoter vector induced greater expression levels in the hippocampus, as measured by stereological estimates of cell numbers and by Western blots, which demonstrated an 11-fold increase. Incorporation of the WPRE also improved transgene expression in primary neuronal cultures. The increased efficiency obtained with vector elements such as the CBA promoter and the WPRE may enhance the ability to genetically modify larger portions of the brain while requiring smaller doses and volumes.

[1]  H. Hauser,et al.  Dicistronic transcription units for gene expression in mammalian cells. , 1993, Gene.

[2]  I. Martins,et al.  Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Leff,et al.  Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  H. Niwa,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.

[5]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[6]  T. Daly,et al.  Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. , 1999, Human gene therapy.

[7]  B. Byrne,et al.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield , 1999, Gene Therapy.

[8]  C. Sumners,et al.  Characterization of Glucocorticoid Type II Receptors in Neuronal and Glial Cultures from Rat Brain , 1990, Journal of neuroendocrinology.

[9]  P. Colosi,et al.  Distribution of AAV-TK following Intracranial Convection-Enhanced Delivery into Rats , 2000, Cell transplantation.

[10]  James M. Wilson,et al.  Humoral Immunity to Adeno-Associated Virus Type 2 Vectors following Administration to Murine and Nonhuman Primate Muscle , 2000, Journal of Virology.

[11]  G. Breese,et al.  Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector , 1996, Brain Research.

[12]  D. Grimm,et al.  Novel tools for production and purification of recombinant adenoassociated virus vectors. , 1998, Human gene therapy.

[13]  M. Dragunow,et al.  Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes , 2001, Gene Therapy.

[14]  R. Samulski,et al.  Selective and rapid uptake of adeno-associated virus type 2 in brain. , 1998, Human gene therapy.

[15]  Donald W. Pfaff,et al.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain , 1994, Nature Genetics.

[16]  M. Weitzman,et al.  Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. , 1999, Human gene therapy.

[17]  H. Gundersen,et al.  Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator , 1991, The Anatomical record.

[18]  J. Feldon,et al.  Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain , 2000, Gene Therapy.

[19]  Ronald L Klein,et al.  Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. , 2002, Human gene therapy.

[20]  M. King,et al.  Neuron-Specific Transduction in the Rat Septohippocampal or Nigrostriatal Pathway by Recombinant Adeno-associated Virus Vectors , 1998, Experimental Neurology.

[21]  R. Chen,et al.  Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. , 1999, Human gene therapy.

[22]  R. Mandel,et al.  Adeno-associated virus vector-mediated gene transfer to somatic cells in the central nervous system. , 2000, Advances in virus research.

[23]  R. Klein,et al.  Adeno-associated virus vectors: activity and applications in the CNS , 2000, Journal of Neuroscience Methods.

[24]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[25]  M. King,et al.  Generation of aberrant sprouting in the adult rat brain by GAP-43 somatic gene transfer , 1999, Brain Research.

[26]  P. Reier,et al.  Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters , 1997, Gene Therapy.

[27]  William Jagust,et al.  Convection-Enhanced Delivery of AAV Vector in Parkinsonian Monkeys; In Vivo Detection of Gene Expression and Restoration of Dopaminergic Function Using Pro-drug Approach , 2000, Experimental Neurology.

[28]  M. King,et al.  Long-term actions of vector-derived nerve growth factor or brain-derived neurotrophic factor on choline acetyltransferase and Trk receptor levels in the adult rat basal forebrain , 1999, Neuroscience.